Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CART19 in r/r B-ALL and B-NHL
NCT05054257Phase 1Recruiting
- Sponsor
- Institute of Hematology and Blood Transfusion
- Start
- Jun 2021
- Primary completion
- Jun 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous CAR19 T lymphocytes in B cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL), sponsored by Institute of Hematology and Blood Transfusion. Primary endpoints: Incidence of adverse events at 2 years and Dose-Limiting Toxicities at 28 days. Started Jun 2021; status: recruiting.
02
Drugs
autologous CAR19 T lymphocytes
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma (B-NHL)
Beyond the preview
Go deeper on NCT05054257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05054257.